Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [ 161 Tb]Tb-PSMA-I&T
Journal of Nuclear Medicine · 2024-08 · 65 (8) · 1231-1238
DOI: 10.2967/jnumed.124.267650 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 11.07.2024. Verfasst von James P Buteau und 18 weiteren Autor:innen. Beteiligte Einrichtung: Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Ca…. Hauptthemen laut MEDLINE: Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; james.buteau@petermac.org…
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Radiopharmaceutical Production and Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Zitieren
APA
Buteau, J. P., Kostos, L., Alipour, R., Jackson, P., McInstosh, L., Emmerson, B., Haskali, M. B., Xie, J., Medhurst, E., Ravi, R., Gonzalez, B. D., Fettke, H., Blyth, B., Furic, L., Owen, K., Sandhu, S., Murphy, D. G., Azad, A. A., & Hofman, M. S. (2024). Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [ 161 Tb]Tb-PSMA-I&T. Journal of Nuclear Medicine, 65(8), 1231-1238. https://doi.org/10.2967/jnumed.124.267650
Vancouver
Buteau JP, Kostos L, Alipour R, Jackson P, McInstosh L, Emmerson B, et al. Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [ 161 Tb]Tb-PSMA-I&T. Journal of Nuclear Medicine. 2024;65(8):1231-1238. doi:10.2967/jnumed.124.267650
BibTeX
@article{Buteau2024,
author = {Buteau, James P and Kostos, Louise and Alipour, Ramin and Jackson, Price and McInstosh, Lachlan and Emmerson, Brittany and Haskali, Mohammad B and Xie, Jing and Medhurst, Elizabeth and Ravi, Rajeev and Gonzalez, Brian D and Fettke, Heidi and Blyth, Benjamin and Furic, Luc and Owen, Katie and Sandhu, Shahneen and Murphy, Declan G and Azad, Arun A and Hofman, Michael S},
title = {Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [ 161 Tb]Tb-PSMA-I&T},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {8},
pages = {1231--1238},
doi = {10.2967/jnumed.124.267650}
}
EUVIMED